Strategies against methicillin-resistant Staphylococcus aureus persisters.

Chronic Staphylococcus aureus infections are complicated by frequent relapses not only from the development of drug resistance to conventional antibiotics, but also through the formation of persister bacterial cells. Bacterial persisters are in a transient, metabolically inactive state, making conventional antibiotics that target essential cellular growth processes ineffective, resulting in high clinical failure rates of antibiotic chemotherapy. The development of new antibiotics against persistent S. aureus is an urgent issue. Over the last decade, new strategies to identify S. aureus persister-active compounds have been proposed. This review summarizes the proposed targets, antipersister compounds and innovative methods that may augment conventional antibiotics against S. aureus persisters. The reviewed antipersister strategies can be summarized as two broad categories; directly targeting growth-independent targets and potentiating existing, ineffective antibiotics by aiding uptake or accessibility.

[1]  Antibiotic resistance threats in the United States, 2019 , 2019 .

[2]  N. Akhtar,et al.  Antimicrobial peptides (AMPs): The quintessential 'offense and defense' molecules are more than antimicrobials. , 2017, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[3]  N. Molchanova,et al.  Advances in Development of Antimicrobial Peptidomimetics as Potential Drugs , 2017, Molecules.

[4]  H. Brötz-Oesterhelt,et al.  Conformational control of the bacterial Clp protease by natural product antibiotics. , 2017, Natural product reports.

[5]  Yousong Ding,et al.  Antimicrobial peptide-inspired NH125 analogues: bacterial and fungal biofilm-eradicating agents and rapid killers of MRSA persisters. , 2017, Organic & biomolecular chemistry.

[6]  Guangshun Wang,et al.  Host defense antimicrobial peptides as antibiotics: design and application strategies. , 2017, Current opinion in chemical biology.

[7]  R. Fisher,et al.  Persistent bacterial infections and persister cells , 2017, Nature Reviews Microbiology.

[8]  M. Seleem,et al.  Targeting biofilms and persisters of ESKAPE pathogens with P14KanS, a kanamycin peptide conjugate. , 2017, Biochimica et biophysica acta. General subjects.

[9]  Hussain Yousaf,et al.  Identification of N‐Arylated NH125 Analogues as Rapid Eradicating Agents against MRSA Persister Cells and Potent Biofilm Killers of Gram‐Positive Pathogens , 2017, Chembiochem : a European journal of chemical biology.

[10]  R. Harvey,et al.  Mechanism of Action of a Membrane-Active Quinoline-Based Antimicrobial on Natural and Model Bacterial Membranes. , 2017, Biochemistry.

[11]  B. Conlon,et al.  Convergence of Staphylococcus aureus Persister and Biofilm Research: Can Biofilms Be Defined as Communities of Adherent Persister Cells? , 2016, PLoS pathogens.

[12]  Gerard D. Wright,et al.  Bacterial proteases, untapped antimicrobial drug targets , 2016, The Journal of Antibiotics.

[13]  N. Chen,et al.  Inhibition of eEF-2 kinase sensitizes human nasopharyngeal carcinoma cells to lapatinib-induced apoptosis through the Src and Erk pathways , 2016, BMC Cancer.

[14]  T. Wood,et al.  DNA‐crosslinker cisplatin eradicates bacterial persister cells , 2016, Biotechnology and bioengineering.

[15]  M. Seleem,et al.  Dual Targeting of Intracellular Pathogenic Bacteria with a Cleavable Conjugate of Kanamycin and an Antibacterial Cell-Penetrating Peptide. , 2016, Journal of the American Chemical Society.

[16]  J. Sello,et al.  A Conformationally Constrained Cyclic Acyldepsipeptide Is Highly Effective in Mice Infected with Methicillin-Susceptible and -Resistant Staphylococcus aureus , 2016, PloS one.

[17]  E. Blackstone,et al.  Current Hypotheses in Cardiac Surgery: Biofilm in Infective Endocarditis. , 2016, Seminars in thoracic and cardiovascular surgery.

[18]  Gerd Geisslinger,et al.  Drug Repurposing for the Development of Novel Analgesics. , 2016, Trends in pharmacological sciences.

[19]  Petia M. Vlahovska,et al.  NH125 kills methicillin-resistant Staphylococcus aureus persisters by lipid bilayer disruption. , 2016, Future medicinal chemistry.

[20]  M. Loessner,et al.  Bacteriophage endolysins: applications for food safety. , 2016, Current opinion in biotechnology.

[21]  Siqiong June Liu,et al.  NH125 reduces the level of CPEB3, an RNA binding protein, to promote synaptic GluA2 expression , 2016, Neuropharmacology.

[22]  Adrian O. Olivares,et al.  Mechanistic insights into bacterial AAA+ proteases and protein-remodelling machines , 2015, Nature Reviews Microbiology.

[23]  P. S. Andersen,et al.  Novel antibody–antibiotic conjugate eliminates intracellular S. aureus , 2015, Nature.

[24]  J. Pedraz,et al.  Pulmonary drug delivery: a review on nanocarriers for antibacterial chemotherapy. , 2015, The Journal of antimicrobial chemotherapy.

[25]  T. Wood,et al.  Combatting bacterial infections by killing persister cells with mitomycin C. , 2015, Environmental microbiology.

[26]  Annie L. Conery,et al.  Identification of an Antimicrobial Agent Effective against Methicillin-Resistant Staphylococcus aureus Persisters Using a Fluorescence-Based Screening Strategy , 2015, PloS one.

[27]  Vance G. Fowler,et al.  Staphylococcus aureus Infections: Epidemiology, Pathophysiology, Clinical Manifestations, and Management , 2015, Clinical Microbiology Reviews.

[28]  K. Lewis,et al.  Borrelia burgdorferi, the Causative Agent of Lyme Disease, Forms Drug-Tolerant Persister Cells , 2015, Antimicrobial Agents and Chemotherapy.

[29]  V. Torchilin,et al.  New Developments in Liposomal Drug Delivery. , 2015, Chemical reviews.

[30]  M. Seleem,et al.  Antimicrobial peptides and peptidomimetics - potent therapeutic allies for staphylococcal infections. , 2015, Current pharmaceutical design.

[31]  Yuquan Wei,et al.  Low-dose cisplatin administration to septic mice improves bacterial clearance and programs peritoneal macrophage polarization to M1 phenotype. , 2014, Pathogens and disease.

[32]  B. Martínez,et al.  Effective Removal of Staphylococcal Biofilms by the Endolysin LysH5 , 2014, PloS one.

[33]  Andrea M. Kasko,et al.  Engineering Persister-Specific Antibiotics with Synergistic Antimicrobial Functions , 2014, ACS nano.

[34]  Sophie Helaine,et al.  Bacterial persisters: formation, eradication, and experimental systems. , 2014, Trends in microbiology.

[35]  V. Fowler,et al.  Where does a Staphylococcus aureus vaccine stand? , 2014, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[36]  G. Peters,et al.  Staphylococcus aureus persistence in non-professional phagocytes. , 2014, International journal of medical microbiology : IJMM.

[37]  Annie L. Conery,et al.  Whole Animal Automated Platform for Drug Discovery against Multi-Drug Resistant Staphylococcus aureus , 2014, PloS one.

[38]  Robert T. Sauer,et al.  Restriction of the Conformational Dynamics of the Cyclic Acyldepsipeptide Antibiotics Improves Their Antibacterial Activity , 2014, Journal of the American Chemical Society.

[39]  David W. Holden,et al.  Internalization of Salmonella by Macrophages Induces Formation of Nonreplicating Persisters , 2014, Science.

[40]  Jin-Ming Yang,et al.  Inhibition of Elongation Factor-2 Kinase Augments the Antitumor Activity of Temozolomide against Glioma , 2013, PloS one.

[41]  Richard D. Smith,et al.  Activated ClpP kills persisters and eradicates a chronic biofilm infection , 2013, Nature.

[42]  Jane D. Single....  Management of Multidrug- resistant organisms in Healthcare settings , 2013 .

[43]  M. Seleem,et al.  Targeting intracellular pathogenic bacteria with unnatural proline-rich peptides: coupling antibacterial activity with macrophage penetration. , 2013, Angewandte Chemie.

[44]  G. Wong,et al.  Antimicrobial peptides and induced membrane curvature: geometry, coordination chemistry, and molecular engineering. , 2013, Current opinion in solid state & materials science.

[45]  K. Lewis.  Platforms for antibiotic discovery , 2013, Nature Reviews Drug Discovery.

[46]  G. Wong,et al.  Molecular basis for nanoscopic membrane curvature generation from quantum mechanical models and synthetic transporter sequences. , 2012, Journal of the American Chemical Society.

[47]  Eric J. Rubin,et al.  Bacterial proteolytic complexes as therapeutic targets , 2012, Nature Reviews Drug Discovery.

[48]  Jin-Ming Yang,et al.  Inhibition of eEF-2 kinase sensitizes human glioma cells to TRAIL and down-regulates Bcl-xL expression. , 2011, Biochemical and biophysical research communications.

[49]  Li Tang,et al.  Translocation of HIV TAT peptide and analogues induced by multiplexed membrane and cytoskeletal interactions , 2011, Proceedings of the National Academy of Sciences.

[50]  H. Sahl,et al.  Antibiotic acyldepsipeptides activate ClpP peptidase to degrade the cell division protein FtsZ , 2011, Proceedings of the National Academy of Sciences.

[51]  Stephen C. West,et al.  DNA interstrand crosslink repair and cancer , 2011, Nature Reviews Cancer.

[52]  E. Kavalali,et al.  NMDA Receptor Blockade at Rest Triggers Rapid Behavioural Antidepressant Responses , 2011, Nature.

[53]  James J. Collins,et al.  Metabolite-Enabled Eradication of Bacterial Persisters by Aminoglycosides , 2011, Nature.

[54]  M. Selsted,et al.  Criterion for amino acid composition of defensins and antimicrobial peptides based on geometry of membrane destabilization. , 2011, Journal of the American Chemical Society.

[55]  G. Ramesh,et al.  Mechanisms of Cisplatin Nephrotoxicity , 2010, Toxins.

[56]  R. Ghirlando,et al.  Acyldepsipeptide antibiotics induce the formation of a structured axial channel in ClpP: A model for the ClpX/ClpA-bound state of ClpP. , 2010, Chemistry & biology.

[57]  Yanmin Hu,et al.  A New Approach for the Discovery of Antibiotics by Targeting Non-Multiplying Bacteria: A Novel Topical Antibiotic for Staphylococcal Infections , 2010, PloS one.

[58]  T. Zendo,et al.  Lactococcal membrane-permeabilizing antimicrobial peptides , 2010, Applied Microbiology and Biotechnology.

[59]  N. Kahya.  Protein-protein and protein-lipid interactions in domain-assembly: lessons from giant unilamellar vesicles. , 2010, Biochimica et biophysica acta.

[60]  Pasquale Stano,et al.  Giant Vesicles: Preparations and Applications , 2010, Chembiochem : a European journal of chemical biology.

[61]  H. Song,et al.  Structures of ClpP in complex with acyldepsipeptide antibiotics reveal its activation mechanism , 2010, Nature Structural &Molecular Biology.

[62]  Bruna Gonçalves Coutinho,et al.  Lysostaphin: A Staphylococcal Bacteriolysin with Potential Clinical Applications , 2010, Pharmaceuticals.

[63]  D. Basu,et al.  Local antibiotic delivery systems for the treatment of osteomyelitis - A review , 2009 .

[64]  I. Chopra,et al.  XF-73, a novel antistaphylococcal membrane-active agent with rapid bactericidal activity. , 2009, The Journal of antimicrobial chemotherapy.

[65]  Henry F. Chambers,et al.  Waves of resistance: Staphylococcus aureus in the antibiotic era , 2009, Nature Reviews Microbiology.

[66]  Christopher T. Walsh,et al.  Antibiotics for Emerging Pathogens , 2009, Science.

[67]  Anne E Carpenter,et al.  High-throughput screen for novel antimicrobials using a whole animal infection model. , 2009, ACS chemical biology.

[68]  T. Coates,et al.  Nasal decolonization of Staphylococcus aureus with mupirocin: strengths, weaknesses and future prospects , 2009, The Journal of antimicrobial chemotherapy.

[69]  W. Kelley,et al.  Staphylococcus aureus: new evidence for intracellular persistence. , 2009, Trends in microbiology.

[70]  Mamta Sharma,et al.  Persistent Staphylococcus aureus bacteremia: Incidence and outcome trends over time , 2009, Scandinavian journal of infectious diseases.

[71]  A. Kramer,et al.  Biocompatibility index of antiseptic agents by parallel assessment of antimicrobial activity and cellular cytotoxicity. , 2008, The Journal of antimicrobial chemotherapy.

[72]  Fred C Tenover,et al.  Changes in the prevalence of nasal colonization with Staphylococcus aureus in the United States, 2001-2004. , 2008, The Journal of infectious diseases.

[73]  Nathalie Q Balaban,et al.  Single-cell protein induction dynamics reveals a period of vulnerability to antibiotics in persister bacteria , 2008, Proceedings of the National Academy of Sciences.

[74]  C. Weidenmaier,et al.  Teichoic acids and related cell-wall glycopolymers in Gram-positive physiology and host interactions , 2008, Nature Reviews Microbiology.

[75]  M. Jackson,et al.  Management of multidrug-resistant organisms in health care settings, 2006. , 2007, American journal of infection control.

[76]  Roberta B Carey,et al.  Invasive methicillin-resistant Staphylococcus aureus infections in the United States. , 2007, JAMA.

[77]  L. Kèlland,et al.  The resurgence of platinum-based cancer chemotherapy , 2007, Nature Reviews Cancer.

[78]  T. Lampe,et al.  Medicinal Chemistry Optimization of Acyldepsipeptides of the Enopeptin Class Antibiotics , 2006, ChemMedChem.

[79]  Frederick M Ausubel,et al.  Identification of novel antimicrobials using a live-animal infection model , 2006, Proceedings of the National Academy of Sciences.

[80]  Arkady Khodursky,et al.  Persisters: a distinct physiological state of E. coli , 2006, BMC Microbiology.

[81]  Jan Borysowski,et al.  Bacteriophage Endolysins as a Novel Class of Antibacterial Agents , 2006, Experimental biology and medicine.

[82]  R. Dziarski,et al.  Peptidoglycan Recognition Proteins Are a New Class of Human Bactericidal Proteins* , 2006, Journal of Biological Chemistry.

[83]  P. Gilbert,et al.  Cationic antiseptics: diversity of action under a common epithet , 2005, Journal of applied microbiology.

[84]  H. Sahl,et al.  Dysregulation of bacterial proteolytic machinery by a new class of antibiotics , 2005, Nature Medicine.

[85]  R. Utsumi,et al.  P-glycoprotein mediates resistance to histidine kinase inhibitors. , 2004, Molecular pharmacology.

[86]  T. Ashburn,et al.  Drug repositioning: identifying and developing new uses for existing drugs , 2004, Nature Reviews Drug Discovery.

[87]  L. Gianni,et al.  Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity , 2004, Pharmacological Reviews.

[88]  R. Pettit.  Soil DNA libraries for anticancer drug discovery , 2004, Cancer Chemotherapy and Pharmacology.

[89]  Paul Stoodley,et al.  Bacterial biofilms: from the Natural environment to infectious diseases , 2004, Nature Reviews Microbiology.

[90]  J. Shetty,et al.  Genetic Analysis of a High-Level Vancomycin-Resistant Isolate of Staphylococcus aureus , 2003, Science.

[91]  T. Ganz.  Defensins: antimicrobial peptides of innate immunity , 2003, Nature Reviews Immunology.

[92]  F. Lowy.  Antimicrobial resistance: the example of Staphylococcus aureus. , 2003, The Journal of clinical investigation.

[93]  R. Utsumi,et al.  Antibacterial Agents that Inhibit Histidine Protein Kinase YycG of Bacillus subtilis , 2001, Bioscience, biotechnology, and biochemistry.

[94]  R. Utsumi,et al.  Identification and Characterization of a Potent Antibacterial Agent, NH125 against Drug-resistant Bacteria , 2000, Bioscience, biotechnology, and biochemistry.

[95]  A. D. Russell,et al.  Antiseptics and Disinfectants: Activity, Action, and Resistance , 1999, Clinical Microbiology Reviews.

[96]  R. Proctor,et al.  Staphylococcus aureus small colony variants are induced by the endothelial cell intracellular milieu. , 1996, The Journal of infectious diseases.

[97]  H. Koshino,et al.  Enopeptin A, a novel depsipeptide antibiotic with anti-bacteriophage activity. , 1991, The Journal of antibiotics.

[98]  T. Dougherty,et al.  Tobramycin uptake in Escherichia coli is driven by either electrical potential or ATP , 1991, Journal of bacteriology.

[99]  B. Issell,et al.  Mitomycin: ten years after approval for marketing. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[100]  H. Kaback,et al.  Membrane potential and gentamicin uptake in Staphylococcus aureus. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[101]  H. Marumo,et al.  Isolation of new fractions of antitumor mitomycins. , 1958, Antibiotics & chemotherapy.

[102]  J. Bigger.  TREATMENT OF STAPHYLOCOCCAL INFECTIONS WITH PENICILLIN BY INTERMITTENT STERILISATION , 1944 .

[103]  E. Abraham,et al.  An Enzyme from Bacteria able to Destroy Penicillin , 1940, Nature.

[104]  S. Choi,et al.  Persistent Staphylococcus aureus Bacteremia A Prospective Analysis of Risk Factors, Outcomes, and Microbiologic and Genotypic Characteristics of Isolates , 2018 .

[105]  T. Wood,et al.  Repurposing the anticancer drug mitomycin C for the treatment of persistent Acinetobacter baumannii infections. , 2017, International journal of antimicrobial agents.

[106]  K. Werdan,et al.  Mechanisms of infective endocarditis: pathogen–host interaction and risk states , 2014, Nature Reviews Cardiology.

[107]  N. Fishman,et al.  Healthcare Infection Control Practices Advisory Committee , 2012 .

[108]  I. Chopra,et al.  Targeting bacterial membrane function: an underexploited mechanism for treating persistent infections , 2010, Nature Reviews Microbiology.

[109]  I. Chopra,et al.  XF-70 and XF-73, novel antibacterial agents active against slow-growing and non-dividing cultures of Staphylococcus aureus including biofilms. , 2010, The Journal of antimicrobial chemotherapy.

[110]  K. Lewis,et al.  Persister cells. , 2010, Annual review of microbiology.

[111]  V. Torchilin.  Multifunctional nanocarriers. , 2006, Advanced drug delivery reviews.

[112]  K. Lewis,et al.  Persister cells and tolerance to antimicrobials. , 2004, FEMS microbiology letters.